Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4391243 | 0.87 | PIK3CD (0.36) | MEN1KMT2APIK3CD | |
| SCHEMBL2760168 | 0.87 | KMT2A (0.41) | MEN1KMT2APOLBPIK3CD | |
| SCHEMBL771784 | 0.86 | ALDH1A1 (0.33) | MEN1KMT2APOLB | |
| SCHEMBL1196154 | 0.83 | — | — | |
| SCHEMBL1408760 | 0.82 | — | — | |
| SCHEMBL11501711 | 0.82 | — | — | |
| SCHEMBL12663243 | 0.80 | MEN1 (0.37) | MEN1KMT2APOLBPIK3CD | |
| Iodide SCHEMBL28268785 | 0.79 | KMT2A (0.44) | MEN1KMT2APOLBPIK3CD | |
| SCHEMBL21540252 | 0.78 | MEN1 (0.35) | MEN1KMT2APOLBPIK3CD | |
| Iodomethane SCHEMBL27939134 | 0.77 | KMT2A (0.43) | MEN1KMT2APOLBPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3862354-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | 4SC AG (DE) | 2021-08-11 | — | — | EP | claimed |
| EP-2824105-B1 | Indolopyridines as Eg5 kinesin modulators | 4SC AG (DE) | 2021-03-31 | — | — | EP | claimed |
| EP-2824105-A1 | Indolopyridines as Eg5 kinesin modulators | 4SC AG (DE) | 2015-01-14 | — | — | EP | claimed |
| US-8530493-B2 | Indolopyridines as Eg5 kinesin modulators | 4SC AG (DE) | 2013-09-10 | — | — | US | claimed |
| CN-101389628-A | Indolopyridines as EG5 kinesin modulators | 4SC AG (DE) | 2009-03-18 | — | — | CN | claimed |
| CN-101389629-A | Indolopyridines as EG5 kinesin modulators | 4SC AG (DE) | 2009-03-18 | — | — | CN | claimed |
| EP-2033962-A1 | Tetracyclic indolopyridines as EG5 inhibitors | 4SC AG (DE) | 2009-03-11 | — | — | EP | claimed |
| EP-3862354-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | 4SC AG (DE) | 2021-08-11 | — | — | EP | disclosed |
| EP-2268640-B1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE INDOLOPYRIDINES | 4SC AG (DE) | 2016-10-12 | — | — | EP | disclosed |
| EP-2824105-A1 | Indolopyridines as Eg5 kinesin modulators | 4SC AG (DE) | 2015-01-14 | — | — | EP | disclosed |
| US-8530493-B2 | Indolopyridines as Eg5 kinesin modulators | 4SC AG (DE) | 2013-09-10 | — | — | US | disclosed |
| CN-101389628-B | Indolopyridines as EG5 kinesin modulators | 4SC AG | 2013-02-27 | — | — | CN | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| WO-2009024190-A1 | INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5 ) | 4SC AG (DE) | 2009-02-26 | — | — | WO | disclosed |
| EP-1996592-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | Nycomed GmbH (DE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1994033-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | 4SC AG (DE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007096395-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | 4SC AG (DE) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007096393-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | 4SC AG (DE) | 2007-08-30 | — | — | WO | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | MEN1 4753/4885KMT2A 1865/4885POLB 77/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | MEN1 4753/4885KMT2A 1865/4885POLB 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.